Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Singapore Institute Of Advanced Medicine Holdings EBITDA Margin % Related Terms
Singapore Institute Of Advanced Medicine Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Singapore Institute Of Advanced Medicine Holdings EBITDA Margin % Chart
Singapore Institute Of Advanced Medicine Holdings Annual Data
Trend
Jun21
Jun22
Jun23
Jun24
Jun25
EBITDA Margin %
-23.67
-58.10
-66.37
-80.61
-76.19
Singapore Institute Of Advanced Medicine Holdings Quarterly Data
SGX:9G2 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Singapore Institute Of Advanced Medicine Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Singapore Institute Of Advanced Medicine Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) has a EBITDA Margin % of -56.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Singapore Institute Of Advanced Medicine Holdings and its competitors. According to the industry distribution chart, Singapore Institute Of Advanced Medicine Holdings ranks #607 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 91.4%.
Is Singapore Institute Of Advanced Medicine Holdings' EBITDA Margin % too high?
Singapore Institute Of Advanced Medicine Holdings' current EBITDA Margin % is -56.62%. Based on the distribution chart, Singapore Institute Of Advanced Medicine Holdings ranks #607 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Singapore Institute Of Advanced Medicine Holdings' EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Singapore Institute Of Advanced Medicine Holdings ranks #607 out of 664 companies for EBITDA Margin %. This places Singapore Institute Of Advanced Medicine Holdings in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Singapore Institute Of Advanced Medicine Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Singapore Institute Of Advanced Medicine Holdings's current EBITDA Margin % is -56.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Singapore Institute Of Advanced Medicine Holdings stock overvalued right now?
Singapore Institute Of Advanced Medicine Holdings (SGX:9G2) has a current EBITDA Margin % of -56.62%. The current EBITDA Margin % is -56.62%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Singapore Institute Of Advanced Medicine Holdings (SGX:9G2), the current EBITDA Margin % is -56.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Singapore Institute of Advanced Medicine Holdings Ltd is a Singapore-based healthcare service provider comprising a medical center, diagnostic imaging facility, nuclear medicine clinic, and radiation oncology service providing proton and X-ray radiotherapy. Its operating segments are: Medical Diagnostics and Treatments, Radiation Therapy and Medical Oncology Services, and Investment Holding. Medical Diagnostics and Treatments include: cancer-related diagnostics and theranostics treatments, general diagnostics and health screening, and aesthetic services. Radiation Therapy encompasses proton beam therapy, photon radiation therapy, and Medical oncology. The majority of the company's revenue comes from the Medical Diagnostics and Treatments segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:9G2 has been successfully added to your 
